GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease

Дата публикации: 13-10-2026 19:40:17

A new Houston Methodist Research Institute study finds that older adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who received GLP-1-based treatment experienced significantly lower risks of liver disease–related complications, hospitalization and death compared with similar patients who did not receive the treatment.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials [version 1; peer review: awaiting peer review]	0	8.78	06-08-2026
2	GLP-1s may improve outcomes in patients with PAD, diabetes	5	7	08-07-2026
3	Protein discovery reveals potential treatment target for common fatty liver disease	0	9.8	19-10-2026
4	GLP-1 Medications May Improve Health in People With PAD and Diabetes	0	9.88	18-08-2026
5	Ozempic delivers major weight loss in adults over 65, study finds	0	9.85	11-05-2026
6	Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition	5	7	17-07-2026
7	Researchers identify high-IgA MASLD subtype linked to liver-related events	0	11.32	09-10-2026
8	GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa	5	7	08-07-2026
9	Link between liver fibrosis in MASLD, ASCVD varies by glycemic status	0	6.8	01-08-2026
10	GLP-1 Agonists May Help People With Diabetes and Long COVID	0	10.36	09-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.87. Источник: medicalxpress.com.